Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

aid, "These Phase 3 results in patients infected with the genotype 1 virus, evaluated together with the previously reported Phase 3 results in patients infected with the genotypes 2 and 3 viruses, suggest that albinterferon alfa-2b has the potential to become an important new treatment option for chronic hepatitis C."

"We are encouraged that albinterferon alfa-2b met the primary efficacy endpoint of non-inferiority to peginterferon alfa-2a in both of our pivotal Phase 3 studies," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "As we found with the earlier results from ACHIEVE 2/3, the ACHIEVE 1 data show that the rate of sustained virologic response was comparable for the treatment group receiving the 900-mcg dose of albinterferon alfa-2b every two weeks, versus the treatment group receiving the standard dose of peginterferon alfa-2a once weekly. Importantly, the rate of serious and/or severe adverse events was also comparable for these treatment groups. We were pleased to see that serious pulmonary adverse events in the 900-mcg group were infrequent and all resolved with cessation of treatment."

Key Topline Findings from ACHIEVE 1

Treatment Group Receiving Albinterferon Alfa-2b 900-mcg Every Two Weeks, vs. Treatment Group Receiving Peginterferon Alfa-2a 180-mcg Every Week

  • Based on an ITT analysis of the treatment group assigned to receive 900-mcg albinterferon alfa-2b every two weeks, the topline results demonstrate that albinterferon alfa-2b met its primary efficacy endpoint of non-inferiority to peginterferon alfa-2a, with 48.2% (213/442) of patients achieving SVR in the 900-mcg albinterferon alfa-2b treatment group, vs. 51.0% (225/441) in the peginterferon alfa-2a treatment group. The primary analysis, which is adjusted for baseline stratification factors, showed a difference in SVR rates of -1.8% (95% CI -8.1%, 4.5%, p=0.000
    '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... N.C. , May 22, 2013 STEPh, ... to announce the launch of their web site ( ... [STEPh Reports].  About STEPh Reports ... in development.  Each STEPh Report assesses ... trials data, projected launch year, company, and specific key ...
(Date:5/22/2013)... MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) would like ... recent company developments. As Medifirst continues to expand its ... shareholders. Integrating social media into its investor relations strategy, ... post updates on Twitter.  The Facebook homepage is Medifirst ... Says CEO Bruce J. Schoengood ...
(Date:5/22/2013)... 2013 Ranbaxy Laboratories Limited (hereafter, Ranbaxy), ... Daiichi Sankyo), announced on May 22 the actions ... address past conduct under prior management ... Sankyo continues to support Ranbaxy in its efforts ... past which led to the investigations by the ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Medifirst Solutions, Inc. Announces Update To Shareholders 2
(Date:5/22/2013)... (PRWEB) May 22, 2013 College ... have access to Adapt Courseware’s new Introduction ... an adaptive framework that responds based on each ... , the provider of comprehensive adaptive online curriculum ... continuing to develop introductory level general education offerings, ...
(Date:5/22/2013)... May 22, 2013 Beginning Aug. 22, ... the Conrad Foundation’s Spirit of Innovation Challenge . ... plan competition, free and open to students ages 13 ... Spirit of Innovation Challenge celebrates the life and entrepreneurial ... on the Moon. The program challenges teens to work ...
(Date:5/22/2013)... health officials from New Zealand, South Africa, Australia, Fiji ... countries to integrate rheumatic fever (RF) and rheumatic heart ... , "RHD was nearly eradicated in wealthy populations at ... a disease of poverty that kills children, adolescents and ... K. Srinath Reddy, President of the World Heart Federation. ...
(Date:5/22/2013)... TUESDAY, May 21 (HealthDay News) -- The overall health ... 10 people either overweight or obese and large numbers ... not exercising, a new government report shows. , , ... and Prevention, the report found Americans continuing to make ... soaring rates of heart disease, diabetes and other chronic ...
(Date:5/22/2013)... of Melbourne said this small increase in cancer risk ... scans in diagnosing and monitoring disease. , The study ... today and involved researchers at eight other centres ... Research on Cancer in Lyon, France. , Professor ... detailed three dimensional pictures to diagnose or exclude disease ...
Breaking Medicine News(10 mins):Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:Governments hold long-overdue meeting on reducing early death from rheumatic heart disease 2Health News:Americans Still Making Unhealthy Choices: CDC 2Health News:Americans Still Making Unhealthy Choices: CDC 3Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2
... (Nasdaq: ISIS ) announced that the Company will ... San Francisco, CA. Stanley T. Crooke, M.D., Ph.D., Chairman ... Company and an update on recent clinical and business activities.The ... on Monday, January 12, 2009. To access the live ...
... the leading,publisher of medical and scientific literature, announced ... American College of Cardiology,(ACC) ( http://www.acc.org ), the ... research. The agreement calls for Elsevier to publish,the ... of Cardiology,(JACC) ( http://www.elsevier.com/locate/jac ), for the ...
... hearty compared to other industries that have experienced massive layoffs lately. ... jobs in a single week, bringing the site,s job count to ... nursing profession, NursingCrossing aims to update its website with each and ... ...
... Jan. 8 Press Ganey Associates, Inc.,today announced ... of patient flow management tools and services for ... by,offering strategic solutions for patient flow issues such ... delayed surgeries, and lack of,available ICU and hospital ...
... Natural Alternatives International, Inc. ("NAI") (Nasdaq: ... marketer of customized nutritional supplements, today announced that ... Weaver,s employment with NAI ended.NAI also announced it ... Wells Fargo Bank. Among other changes the ...
... at Protecting Medicare Beneficiaries Introduced on the First ... Physical therapy services for ... arbitrary financial caps under legislation introduced Tuesday in ... the American Physical Therapy Association (APTA). The Medicare ...
Cached Medicine News:Health News:Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference 2Health News:The American College of Cardiology Renews its Publishing Partnership With Elsevier 2Health News:The American College of Cardiology Renews its Publishing Partnership With Elsevier 3Health News:NursingCrossing Posts 12,000-Plus Nursing Jobs in a Week; Stresses the Need for Better Training and Working Conditions for Nurses 2Health News:NursingCrossing Posts 12,000-Plus Nursing Jobs in a Week; Stresses the Need for Better Training and Working Conditions for Nurses 3Health News:Press Ganey Acquires PatientFlow Technology 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 3
... the hand, the Jarvik 2000 pump is about ... welded titanium shell sits a direct-current motor, a ... single moving part: a small, spinning titanium impeller ... to 7 liters per minute. Rather than take ...
... cardiac assist system primarily designed as a permanent ... failure., ,It is a blood pump that connects ... to help the ailing hearts pumping function and ... , ,It can also be used as a ...
... The Masimo SET LNOP Blue Sensor is ... babies. The LNOP Blue sensor is ... accuracy claims for cyanotic infants and children. ... presented challenging conditions for reliable and accurate ...
... The Trinity Biotech Captia™ Varicella-Zoster Virus (VZV) ... for the detection and quantitative determination of ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
Medicine Products: